MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

A

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

89.16 -5.01

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

89.14

Max

93.83

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-36M

-128M

Pardavimai

16M

281M

Pelnas, tenkantis vienai akcijai

-0.5

Pelno marža

-45.684

Darbuotojai

2,490

EBITDA

-37M

-119M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+41.45% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-2.3B

11B

Ankstesnė atidarymo kaina

94.17

Ankstesnė uždarymo kaina

89.16

Naujienos nuotaikos

By Acuity

50%

50%

170 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-06 23:17; UTC

Uždarbis

Samsung Forecasts Record First-Quarter Operating Profit

2026-04-06 23:00; UTC

Karštos akcijos

Stocks to Watch: Health Insurers, Mawson, Owlet

2026-04-06 22:13; UTC

Pagrindinės rinkos jėgos

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026-04-06 21:46; UTC

Įsigijimai, susijungimai, perėmimai

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026-04-06 17:09; UTC

Pagrindinės rinkos jėgos

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026-04-06 16:56; UTC

Svarbiausios naujienos

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026-04-06 14:47; UTC

Pagrindinės rinkos jėgos

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026-04-07 00:00; UTC

Svarbiausios naujienos

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026-04-06 23:58; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026-04-06 23:50; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026-04-06 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026-04-06 23:15; UTC

Rinkos pokalbiai

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-06 22:52; UTC

Rinkos pokalbiai

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026-04-06 22:14; UTC

Rinkos pokalbiai

Correction to Live Cattle Futures Article

2026-04-06 20:56; UTC

Rinkos pokalbiai

Mexican Private Consumption Fell in January -- Market Talk

2026-04-06 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2026-04-06 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-06 19:58; UTC

Rinkos pokalbiai

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026-04-06 19:11; UTC

Rinkos pokalbiai

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026-04-06 19:06; UTC

Rinkos pokalbiai

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-04-06 19:03; UTC

Rinkos pokalbiai

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026-04-06 18:36; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 17:59; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026-04-06 17:13; UTC

Įsigijimai, susijungimai, perėmimai

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026-04-06 16:33; UTC

Rinkos pokalbiai

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026-04-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-06 14:59; UTC

Uždarbis

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

41.45% į viršų

12 mėnesių prognozė

Vidutinis 132.72 USD  41.45%

Aukščiausias 175 USD

Žemiausias 110 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

170 / 349 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat